UC Irvine Health
School of Medicine

Fenofibrate as a treatment for Huntington's disease

Study Title: A Phase IIA, Randomized, Double-blind, Placebo-controlled study of the safety and efficacy of fenofibrate as a treatment for Huntington's Disease

Purpose: To study the safety and efficacy of fenofibrate, an FDA approved drug to treat cholesterol, as a treatment for Huntington's disease (HD)

Study drug: 145mg of fenofibrate vs. placebo (75% chance of active drug; 25% chance of placebo)

Duration of study: 6 months with 8 in-clinic visits

Inclusion criteria:

- Age 18 or older
- Clinical findings of Huntington's disease (HD) *and* a confirmed family history of HD ***OR*** Clinical findings of HD *and* a CAG repeat of ≥ 36
- Good overall health status
- Must be able to take oral medication

Exclusion criteria:

- Diagnosis of another major neurological disease (e.g., multiple sclerosis, Parkinson's disease, cortical stroke)
- History of gallstones
- History of known sensitivity to any fibrate medication
- Exposure to another investigational medicine within 30 days prior to baseline visit
- Current or recent (within 3 months of screening visit) use of dopamine blocking agents such as: tetrabenazine, antipsychotics, metoclopramide, prochlorperazine, or HAART
- Current use of Warfarin (Coumadin)
- Current use of statins (e.g., simvastatin, atorvastatin, etc.)
- Are pregnant or lactating

Please note: the above may not be a complete list of inclusion and/or exclusion criteria

For more information, please contact the UC Irvine Neurology Clinical Trials Unit at one of the following:

(949) 824 – 3485
(949) 824 – 7524
Everlyne Gomez: everlyng@uci.edu